PDSB PDS Biotechnology Corporation

$PDSB When PDSB discontinued its Phase 3 trial, I completely lost hope. I mentally wrote off my investment because constantly thinking about my losses would only bring frustration and regret. Then, out of nowhere, Dr. Patrick Soon-Shiong’s investment, the PDS0101 licensing discussions, and the plans for PDS0301 Phase 3 gave me hope again. I started buying more shares and significantly averaged down. Now, I’m almost back in the green, but I have no intention of selling a single share. I’ve been through the worst, and now I want to see where this journey takes us. I trust Dr. PSS, I believe in the science, and I believe the best is yet to come.

$PDSB After compliance the next business day notification, announcement or PR. Monday. Shorts were almost successful in ruining a potential Cancer Cure. Big Pharma does not make money on cures Pays low life posters to slam, degrade. Dr. PSS has saved this and according to the recent information Phase 3 will be submitted this quarter. 11 Million bucks

$PDSB If clinical progress on PDS0301 accelerates, Dr. PSS may execute the PDS0101 agreement early to consolidate the entire pipeline under his umbrella. $100-$250 million if PSS opts to outright buy PDS0101. It would be prudent for Nant/$IBRX buy them out. 👉

$PDSB This isn’t just about adding directors. $PDSB is strengthening its leadership with people who have successfully negotiated major pharmaceutical partnerships, navigated regulatory challenges, and executed billion-dollar transactions. With Dr. Patrick Soon-Shiong already involved, the combination of scientific, regulatory, and dealmaking expertise is particularly encouraging. Could this be positioning $PDSB for a major partnership or strategic transaction? Nothing is guaranteed, but the direction is certainly worth watching. 🚀 $PDSB $IBRX ⸻

$PDSB This isn’t going back down. This is so strong. None of their lies can take this out. We got the winner.

$PDSB H.C. Wainwright: Analyst Joseph Pantginis reiterated a Buy rating and a $5.00 price target on October 15, 2026 for PDSB, The firm noted that the updated PDS0301 clinical data and clarified Phase 3 regulatory framework significantly de-risk the company's oncology pipeline.

$PDSB Friends and fellow investors as per the news today IBRX and PDSB I conclude that the two companies are going to merge. Two members of ImmunityBio have joined the board of directors of PDS Biotechnology. Dr. Patrick and Bruce Wendel.

$PDSB I bought more today. Fundamentally nothing has changed. Dr. PSS is still onboard. The Nasdaq compliance PR will come out in the next couple days and this will rebound. This is a great buying opportunity.

$PDSB ...when this stock starts moving up, it could move fast!! Above $5/sh very possible short term! BOL to us, Longs!!

$PDSB nice to see the bleeding stop. Maybe now we’ll see a nice steady rise back to $1.5. No rush here

$PDSB The data presented on 10/15/26 by Dr. Hernandez for metastatic colon cancer was amazing. This study, and the follow-up, which is to begin in 1Q 2027, are run by and paid for by the NIH. That is incredibly valuable. PSS science has nothing to do with this HAIP metastatic colon cancer indication for 0301. Dr. Hernandez seems very important to our future. I hope PSS is too. And maybe Ted Ross one day out of the blue.

$PDSB AH is fake news! I’ll sleep comfortably knowing that maybe not tomorrow, next week or even next month, but the SP is going to be over $2 in the near future.

$PDSB Yes and what makes this even more interesting is how PDS0301 inhibits harmful IL-12 inflammatory cytokines. This is why Dr. PSS $IBRX has an interest here!

$PDSB Really think Dr Soon-Shiong is one and done here with $22M? No, he understands the science and sees vision of IL-15, IL-12, NK Cell combo!

$PDSB praying for my fellow longs that we getting more good news end of year, have a nice weekend

$PDSB phase 2 pds0301 metastatic colorectal cancer with liver metastasis non-resectable 80% survival 24 months vs under 40% with current protocol. Current MC od under 100mil. It is a goldmine in my opinion. Money is in the hold!

$PDSB Ok I am officially back on this dip. Got back in heavy. I have so much love for this stock. Guys/gals, also check out $CYDY. Its gaining momentum and remind me of pdsb when it was in he 20-30 cent range

$PDSB $IBRX 's been a board shake-up at PDS Biotechnology (PDSB), the company where Nant Capital owns 15% or more after its September share purchase. Four longtime directors resigned effective Oct 18 and three new ones were appointed. Nant's two board picks now chair key committees: Dr. Soon-Shiong runs Compensation and NantBio's CFO James Banaag runs Audit. My read is that Nant is tightening its control there. This doesn't directly affect IBRX.

$PDSB eyes on the stock and volume is on our side since PSS involvement..just need news to send it🤞

$PDSB ok so Friday October 16 was the 10th day that the stock stayed above a dollar. When the PR gets released that they are back in compliance this will shoot up like a rocket. 🚀